viewFSD Pharma

FSD Pharma nets C$400,000 from sale of Pharmadrug stake

The buyer also has an option before June 26 to purchase an additional 5 million shares for C$500,000

FSD Pharma - FSD Pharma nets C$400,000 from sale of Pharmadrug stake
The company said it may consider divesting the balance of its Pharmadrug stake through open market transactions

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE.CN) (FRA:0K9A) said it has sold 5 million Pharmadrug Inc (CSE:BUZZ) shares in a privately negotiated transaction at C$0.08 per share realising cash proceeds of C$400,000.

Under the terms of the sale, the buyer also has an option before June 26 to purchase an additional 5 million shares at a price of C$0.10 each from FSD for C$500,000.

READ: FSD Pharma closes out 1Q with C$8.4 million in cash after liquidating equity interest in Cannara Biotech

The company said it may consider the divestiture of the balance of its equity stake in Pharmadrug through open market transactions, having initially held 13.5 million Pharmadrug shares in April 2019.

In a statement, FSD Pharma managing director, executive co-chairman and chief executive Raza Bokhari said: "We are pleased to finalize this transaction as part of our continuing efforts to strengthen disposable cash on our balance sheet primarily to support our pharmaceutical R&D program. We plan to continue to shore up our cash position by strategically divesting non-cash assets, and raising new capital, either through private placement, debt financing or registered offering of our Class B subordinate voting stock."

FSD Pharma is a biotech firm which through its subsidiary FSD BioSciences is focused on developing a pipeline of FDA-approved synthetic compounds targeting the endocannabinoid system of the human body to treat certain diseases of the central nervous system and autoimmune disorders of the skin, GI tract, and the musculoskeletal system.

The company is also developing opioid-sparing prescription drugs through its Prismic Pharmaceuticals firm, as well as cannabis cultivation through another subsidiary, FV Pharma.

Contact the author at [email protected]

Follow him on Twitter at @Cal_Proac

Quick facts: FSD Pharma

Price: 4.25 CAD

Market: CSE
Market Cap: $36.96 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of FSD Pharma named herein, including the promotion by the Company of FSD Pharma in any Content on the Site, the Company receives from said issuer...



Full interview: FSD Pharma 'thrilled' to begin Phase 1 studies of its...

FSD Pharma Inc (NASDAQ:HUGE) (CSE:HUGE) BioSciences Division President Dr Ed Brennan tells Proactive the company has begun a Phase 1 human study of its anti-inflammatory ultra-micronized-palmitoylethanolamide (PEA) after winning approval from the Ethics Committee of the Alfred Hospital in...

on 11/3/20

2 min read